162 related articles for article (PubMed ID: 7104169)
1. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol.
Daneshmend TK; Roberts CJ
Br J Clin Pharmacol; 1982 Jul; 14(1):73-8. PubMed ID: 7104169
[TBL] [Abstract][Full Text] [Related]
2. The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics.
Daneshmend TK; Roberts CJ
Br J Clin Pharmacol; 1984 Sep; 18(3):393-400. PubMed ID: 6487478
[TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics of labetalol in healthy young men.
Nyberg G; Hansson R; Tietz F
Acta Med Scand Suppl; 1982; 665():67-73. PubMed ID: 6961762
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol.
Elliott HL; Meredith PA; Sumner DJ; Reid JL
Br J Clin Pharmacol; 1984 May; 17(5):573-8. PubMed ID: 6145441
[TBL] [Abstract][Full Text] [Related]
5. Decreased first-pass metabolism of labetalol in chronic liver disease.
Homeida M; Jackson L; Roberts CJ
Br Med J; 1978 Oct; 2(6144):1048-50. PubMed ID: 709214
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of labetalol in healthy volunteers.
Kanto J; Allonen H; Kleimola T; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1981 Jan; 19(1):41-4. PubMed ID: 7203731
[TBL] [Abstract][Full Text] [Related]
7. Effect of food on the bioavailability of labetalol.
Mäntylä R; Allonen H; Kanto J; Kleimola T; Sellman R
Br J Clin Pharmacol; 1980 Apr; 9(4):435-7. PubMed ID: 7378263
[No Abstract] [Full Text] [Related]
8. Bioavailability of labetalol increases with age.
Kelly JG; McGarry K; O'Malley K; O'Brien ET
Br J Clin Pharmacol; 1982 Aug; 14(2):304-5. PubMed ID: 7104187
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.
McNeil JJ; Anderson AE; Louis WJ; Morgan DJ
Br J Clin Pharmacol; 1979; 8(Suppl 2):157S-161S. PubMed ID: 526397
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of labetalol.
McNeil JJ; Louis WJ
Clin Pharmacokinet; 1984; 9(2):157-67. PubMed ID: 6370541
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of labetalol in patients with end-stage renal disease.
Luke DR; Awni WM; Halstenson CE; Opsahl JA; Matzke GR
Ther Drug Monit; 1992 Jun; 14(3):203-8. PubMed ID: 1412606
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of dilevalol.
Tenero DM; Bottorff MB; Given BD; Kramer WG; Affrime MB; Patrick JE; Lalonde RL
Clin Pharmacol Ther; 1989 Dec; 46(6):648-56. PubMed ID: 2598569
[TBL] [Abstract][Full Text] [Related]
13. Labetalol disposition and concentration-effect relationships during pregnancy.
Rubin PC; Butters L; Kelman AW; Fitzsimons C; Reid JL
Br J Clin Pharmacol; 1983 Apr; 15(4):465-70. PubMed ID: 6849783
[TBL] [Abstract][Full Text] [Related]
14. Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension.
Louis WJ; Christophidis N; Brignell M; Vijayasekaran V; McNeil J; Vajda FJ
Aust N Z J Med; 1978 Dec; 8(6):602-9. PubMed ID: 285681
[No Abstract] [Full Text] [Related]
15. Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.
Joekes AM; Thompson FD
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):789-93. PubMed ID: 990156
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers.
Kramer WG; Nagabhushan N; Affrime MB; Perentesis GP; Symchowicz S; Patrick JE
J Clin Pharmacol; 1988 Jul; 28(7):644-8. PubMed ID: 3216030
[TBL] [Abstract][Full Text] [Related]
17. The use of labetalol as a moderate hypotensive agent in otological operations--plasma concentrations after intravenous administration.
Kanto J; Pakkanen A; Allonen H; Kleimola T; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):191-4. PubMed ID: 7390669
[TBL] [Abstract][Full Text] [Related]
18. Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.
Ronne-Rasmussen JO; Andersen GS; Jensen NB; Andersson E
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):805-8. PubMed ID: 990157
[TBL] [Abstract][Full Text] [Related]
19. Elimination kinetics of labetalol in severe renal failure.
Wood AJ; Ferry DG; Bailey RR
Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):81S-86S. PubMed ID: 7093103
[TBL] [Abstract][Full Text] [Related]
20. The metabolism of labetalol in animals and man.
Hopkins R; Martin LE; Bland R
Biochem Soc Trans; 1976; 4(4):726-9. PubMed ID: 1001750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
